share_log

Chardan Capital Maintains Buy on Passage Bio, Lowers Price Target to $9

Chardan Capital Maintains Buy on Passage Bio, Lowers Price Target to $9

Chardan Capital維持對Passage Bio的買入,將目標股價下調至9美元
Benzinga ·  2023/08/08 04:28

Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $11 to $9.

Chardan Capital分析師Geulah Livshits維持Passage Bio(納斯達克股票代碼:PASG)的買入,並將目標股價從11美元下調至9美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論